FHI 360 is working to prevent, detect and treat drug-resistant tuberculosis (DR-TB) through the Global Resilience Against Drug-Resistant Tuberculosis (GRAD-TB) project. FHI 360 will provide technical assistance to local partners and ministries of health in 24 USAID-designated priority countries and 31 Global Fund Technical Assistance countries to address the drug-resistant tuberculosis (DR-TB) epidemic.
While management of DR-TB has greatly improved over the past decade, access to quality care remains limited. Currently, less than 30% of individuals with DR-TB are detected and treated across the entire continuum of care — far lower than global standards.
To address this gap and continue working toward a world free of TB, GRAD-TB is partnering with governments, local organizations and the private sector in multiple countries to strengthen local capacity to lead the DR-TB response and to improve governments’ DR-TB programs. The project is also developing on-demand tools, evidence-based approaches, and tailored trainings for partners so that countries have what they need to sustainably lead their TB response.
The consortium partners are Partners in Health (PIH), Interactive Research and Development (IRD), Treatment Action Group (TAG), Foundation for Professional Development (FPD) and Viamo.
FHI 360’s TB work brings together more than 120 staff members across 30 countries and will be expanded by GRAD-TB.
